2,408
Total Claims
$1.3M
Drug Cost
371
Beneficiaries
$3,481
Cost/Patient
Peer Comparison vs. 6,382 Endocrinology providers
-11%
Cost per patient vs peers
$3,481 vs $3,933 avg
+14%
Brand preference vs peers
58.5% vs 51.2% avg
Brand vs Generic
42% generic
Brand: 1,253 claims · $1.2M
Generic: 890 claims · $46K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 102 | $150K |
| Insulin Glargine,hum.Rec.Anlog | 207 | $149K |
| Empagliflozin | 95 | $147K |
| Insulin Lispro | 117 | $143K |
| Teriparatide | 25 | $109K |
| Sitagliptin Phosphate | 63 | $91K |
| Liraglutide | 20 | $61K |
| Semaglutide | 28 | $43K |
| Insulin Aspart | 49 | $40K |
| Insulin Degludec | 18 | $31K |
| Insulin Lispro | 12 | $26K |
| Linagliptin | 16 | $24K |
| Cinacalcet Hcl | 18 | $21K |
| Insulin Glargine,hum.Rec.Anlog | 38 | $20K |
| Pen Needle, Diabetic | 138 | $17K |
Prescribing Profile
Patient Profile
71
Avg Age
66%
Female
1.54
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About